Short-course therapy for tuberculosis in infants and children

April 1994
CMAJ: Canadian Medical Association Journal;4/15/1994, Vol. 150 Issue 8, p1233
Academic Journal
No abstract available.


Related Articles

  • Short-course therapy for tuberculosis in infants and children. Smith, Jeanette M. // JAMA: Journal of the American Medical Association;6/22/94-6/29/94, Vol. 271 Issue 24, p1890c 

    Presents a recommended short-course pediatric therapy for tuberculosis. Aim of improving efficacy of and compliance with therapy for tuberculosis in children; Development of drug resistance and compliance with treatment; Benefits, harms and costs; Therapy regimens with specific types of...

  • Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost-Effectiveness Analysis Based on a Multicenter Clinical Trial. Ijaz, Kashet; McElroy, Peter D.; Navin, Thomas R. // Clinical Infectious Diseases;7/15/2004, Vol. 39 Issue 2, p289 

    Presents a letter to the editor appreciating a clinical analysis of short-course rifampin and pyrazinamide therapy for tuberculosis.

  • A Review of Efficacy Studies of 6-Month Short-Course Therapy for Tuberculosis among Patients Infected with Human Immunodeficiency Virus: Differences in Study Outcomes. El-Sadr, Wafaa M.; Perlman, David C.; Denning, Eileen; Matts, John P.; Cohn, David L. // Clinical Infectious Diseases;2/15/2001, Vol. 32 Issue 4, p623 

    Deals with a study which reviewed efficacy researches of short-course therapy for tuberculosis among patients infected with HIV. Overview of the impact of HIV epidemic on incidence of tuberculosis; Methodology; Results and discussion.

  • Effectiveness of short-course, intermittent chemotherapy for tuberculosis in young infants aged... Kiper, Nural; Göçmen, Ayhan; Dilber, Embiya; Özçelik, U&gcaron;ur // Clinical Pediatrics;Jul1998, Vol. 37 Issue 7, p433 

    Determines the efficacy of short-course, intermittent chemotherapy for tuberculosis in young infants less than 6 months of age. Isoniazid and Rifampin treatments with and without streptomycin; Follow-up period; Lack of patient's demonstration of relapse.

  • CDC recommends four-drug treatment of tuberculosis in multidrug-resistant era.  // American Family Physician;9/15/1993, Vol. 48 Issue 4, p671 

    Reports on the Advisory Council for the Elimination of Tuberculosis' (ACET) updating of recommendations from the Centers for Disease Control and Prevention for the treatment of tuberculosis. In vitro drug susceptibility testing of Mycobacterium tuberculosis; Initial four-drug treatment; Direct...

  • SHORT-COURSE HAART HAS FLAWS.  // AIDS Patient Care & STDs;Jun2002, Vol. 16 Issue 6, p301 

    Examines the use of Highly Active Anti-Retroviral Therapy regimen on infants born to African mothers from contracting HIV infection in the womb. Acquisition of HIV by infants through breastfeeding; Limitation of short-course therapy to labor and delivery due to economic reasons; Percentage of...

  • Strengthening `DOTS' through community care for tuberculosis. Squire, S. Bertel; Wilkinson, David // BMJ: British Medical Journal (International Edition);11/29/97, Vol. 315 Issue 7120, p1395 

    Editorial. Suggests the strengthening of directly observed treatment short-course (DOTS) as the World Health Organization's (WHO) current global tuberculosis control strategy. Global epidemiology of tuberculosis; Elements of WHO's strategy; Predictors of success; Relation of accessibility of...

  • TB prevalence down 30% in China after DOTS.  // Bulletin of the World Health Organization;Sep2004, Vol. 82 Issue 9, p716 

    Cites a study showing the decline of the prevalence of tuberculosis in China after the implementation of the directly observed therapy, short-course (DOTS) control strategy. Estimated number of at risk population receiving the treatment program; Need to improve the detection rate of tuberculosis.

  • The New White Plague. Walton, David; Farmer, Paul // JAMA: Journal of the American Medical Association;12/6/2000, Vol. 284 Issue 21, p2789 

    Comments on mycobacterium tuberculosis (MDRTB) and on how the disease has increased in prevalence internationally. Resistance of the disease to multiple first-line drugs; Use of the directly observed therapy, short-course (DOTS) and its rates of success; How tuberculosis remains the leading...

  • Health agency pulls back on 'patronizing' approach to TB treatment. Mandavilli, Apoorva // Nature Medicine;Mar2007, Vol. 13 Issue 3, p269 

    The article reports on the reliance of the World Health Organization (WHO) on Direct Observed Therapy Short-course (DOTS), to fight tuberculosis (TB). The idea behind DOTS is that a healthcare worker should directly observe those infected swallow the TB drugs at least for the first two months of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics